Aberdeen Group’s Silence Therapeutics SLN Stock Holding History

Aberdeen Group’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.77M	Buy	+201,900	New	+$2.46M	﹤0.01%	864

Other funds holding SLN

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57.1B AUM 43.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Aberdeen Group's SLN Position: Q3 2026 in Review

Aberdeen Group opened a new position in Silence Therapeutics (SLN) in Q3 2026: 201,900 shares worth $1.77M. The stake represents ﹤0.01% of the portfolio and ranks #864 among its holdings.

16 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

Aberdeen Group held 201,900 shares of Silence Therapeutics worth $1.77M as of Q3 2026.
Silence Therapeutics was a new Aberdeen Group position in Q3 2026.
Silence Therapeutics made up ﹤0.01% of Aberdeen Group's portfolio in Q3 2026, its #864 holding.
16 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.